ERBB3 and breast carcinoma: Consistent with this finding, the targeting of HER3 by conditional knockout or using LNA-based antisense molecules inhibits lung adenocarcinoma tumour growth [22] as well as ceases disease progression and prolongs survival in xenograft mouse models of ovarian cancer [20] or HER2-overexpressing breast cancer [23].